reboxetine has been researched along with nomifensine in 6 studies
| Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (nomifensine) | Trials (nomifensine) | Recent Studies (post-2010) (nomifensine) |
|---|---|---|---|---|---|
| 626 | 193 | 184 | 1,127 | 111 | 65 |
| Protein | Taxonomy | reboxetine (IC50) | nomifensine (IC50) |
|---|---|---|---|
| D | Rattus norvegicus (Norway rat) | 2.724 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 2.724 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.631 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.1642 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 2.724 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 2.724 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 8.7096 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 3.115 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.0316 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 2.724 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.0781 | |
| Transporter | Rattus norvegicus (Norway rat) | 2.7033 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dziedzicka-Wasylewska, M; Filip, M; Inan, SY; Przegaliński, E; Wydra, K | 1 |
| Cardenas, S; Caviedes, P; Graumann, R; Martinez-Alvarado, P; Olea-Azar, C; Paris, I; Perez-Pastene, C; Raisman-Vozari, R; Segura-Aguilar, J; Vieira, MN | 1 |
| Itakura, C; Katayama, M; Niimi, K; Takahashi, E | 1 |
| Blier, P; El Mansari, M; Guiard, BP; Katz, NS | 1 |
| Borgkvist, A; Feltmann, K; Lindskog, M; Malmlöf, T; Schilström, B | 1 |
| Buoli, M; Cahn, W; Serati, M | 1 |
1 review(s) available for reboxetine and nomifensine
| Article | Year |
|---|---|
Alternative pharmacological strategies for adult ADHD treatment: a systematic review.
Topics: Adrenergic alpha-Agonists; Adult; Amphetamines; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Bupropion; Central Nervous System Stimulants; Desipramine; Dopamine Agents; Droxidopa; Drug Combinations; Duloxetine Hydrochloride; Guanfacine; Histamine Agents; Humans; Lisdexamfetamine Dimesylate; Lithium Compounds; Lobeline; Mecamylamine; Memantine; Modafinil; Morpholines; Nicotinic Agonists; Nicotinic Antagonists; Nomifensine; Paroxetine; Pyridines; Pyridoxine; Pyrrolidonecarboxylic Acid; Quinazolinones; Reboxetine; Venlafaxine Hydrochloride; Wakefulness-Promoting Agents | 2016 |
5 other study(ies) available for reboxetine and nomifensine
| Article | Year |
|---|---|
Opioid and monoamine systems mediate the discriminative stimulus of tramadol in rats.
Topics: Adrenergic Uptake Inhibitors; Analgesics, Opioid; Animals; Antidepressive Agents; Biogenic Monoamines; Conditioning, Operant; Cyclohexanols; Cyclopropanes; Discrimination, Psychological; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Fluoxetine; Male; Milnacipran; Morphine; Morpholines; Naloxone; Narcotic Antagonists; Nomifensine; Rats; Rats, Wistar; Reboxetine; Receptors, Opioid, mu; Selective Serotonin Reuptake Inhibitors; Sodium Chloride; Tramadol; Venlafaxine Hydrochloride | 2004 |
Monoamine transporter inhibitors and norepinephrine reduce dopamine-dependent iron toxicity in cells derived from the substantia nigra.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Catecholamine Plasma Membrane Transport Proteins; Cell Death; Cells, Cultured; Chlorides; Dicumarol; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Electron Spin Resonance Spectroscopy; Embryo, Mammalian; Enzyme Inhibitors; Ferric Compounds; Fluorescent Antibody Technique; Imipramine; Indolequinones; Iron; Iron Isotopes; Membrane Glycoproteins; Membrane Transport Modulators; Membrane Transport Proteins; Microscopy, Confocal; Models, Biological; Morpholines; Nerve Tissue Proteins; Neurons; Nomifensine; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Rats; Rats, Inbred F344; Rats, Wistar; Reboxetine; Serotonin Plasma Membrane Transport Proteins; Sodium; Substantia Nigra; Symporters; Thiobarbituric Acid Reactive Substances; Tyrosine 3-Monooxygenase | 2005 |
Additive subthreshold dose effects of cannabinoid CB(1) receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Male; Mice; Mice, Inbred CBA; Models, Animal; Morpholines; Motor Activity; Nomifensine; Piperidines; Pyrazoles; Reboxetine; Receptor, Cannabinoid, CB1; Rimonabant; Selective Serotonin Reuptake Inhibitors; Sertraline; Swimming | 2008 |
Effects of acute and sustained administration of the catecholamine reuptake inhibitor nomifensine on the firing activity of monoaminergic neurons.
Topics: Action Potentials; Adrenergic Uptake Inhibitors; Animals; Delayed-Action Preparations; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Electrophysiological Phenomena; Locus Coeruleus; Male; Morpholines; Neurons; Neurotransmitter Uptake Inhibitors; Nomifensine; Norepinephrine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Reboxetine; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Serotonin; Time Factors; Ventral Tegmental Area | 2010 |
Dopamine in the hippocampus is cleared by the norepinephrine transporter.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Amphetamine; Animals; Cocaine; Dopamine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Drug Administration Routes; Drug Interactions; Hippocampus; Idazoxan; Male; Microdialysis; Morpholines; Nomifensine; Norepinephrine Plasma Membrane Transport Proteins; Raclopride; Rats; Rats, Wistar; Reboxetine; Sodium Channel Blockers; Tetrodotoxin; Time Factors; Wakefulness | 2012 |